Bullish Points: 1. Monogram Orthopaedics is in the early stage of development and primarily focuses on developing patient-optimized orthopedic implants using 3D printing and robotics. 2. The company raised $21,129,000 from the sale of 3,154,786 shares of Series B Preferred Stock in the Series B Offering, which was terminated on February 18, 2022. 3. Monogram commenced a Regulation Crowdfunding offering (Series C Offering) on July 14, 2022, seeking up to $5,000,000 from the sale of Series C Preferred Stock. As of the report date, the company has sold approximately 72,228 shares of Series C Preferred Stock for gross proceeds of $723,002. 4. The primary addressable market for Monogram Orthopaedics is knee procedures, specifically primary Total Knee Arthroplasty (T.K.A.) procedures. 5. Monogra

Bullish Points: 1. Monogram Orthopaedics generated $628,000 in revenue from the sale of licensed implants in the first six months of 2021. 2. The company had a gross profit of $167,771 for the first six months of 2021. 3. As of June 30, 2021, Monogram Orthopaedics had cash on hand of $6,216,312, positive working capital of approximately $3,782,000, and stockholders' equity of $6,055,159. 4. The company raised approximately $6,668,000 in gross proceeds from the Series B Preferred Stock offering through June 30, 2021. 5. Monogram Orthopaedics plans to submit a first-generation press-fit implant for FDA approval by Q2 2022. 6. The company is focusing on cementless knee fixation and expects procedure volumes to increase, driven by demographic tailwinds and rising adoption of uncemented implant

Bullish Points: Monogram Orthopaedics Inc (MGRM) successfully sold 3,642,142 securities in the offering at a price of $4.00 per security, resulting in net proceeds to the issuer of $13,233,968.00. This capital infusion could positively impact the company's future growth and stock price. Bearish Points: There are no explicitly negative points mentioned in the provided keypoints. However, it is essential to analyze the company's financial report thoroughly to identify any potential risks or challenges that could negatively impact the company's future stock price. The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical. For more information, you can read the original text of Monogram Orthopaedics Inc's financial report: https://www

Bullish Points: - Monogram Orthopaedics Inc. successfully sold 3,154,786 securities in the offering. - The company raised a significant amount of net proceeds, totaling $20,339,485. Bearish Points: - No negative points were provided in the keypoints. Based on the information provided, Monogram Orthopaedics Inc. has successfully raised funds through the sale of securities. However, it is essential to consider other factors and conduct further research to make a comprehensive assessment of the company's financial situation. For more information, you can read the original text of Monogram Orthopaedics Inc.'s financial report: https://www.sec.gov/Archives/edgar/data/1769759/000110465922053431/xsl1-K_X01/primary_doc.xml

Bullish Points: There are no specific positive keypoints provided in the input to analyze the potential positive impact on Monogram Orthopaedics Inc's future stock price. Bearish Points: There are no specific negative keypoints provided in the input to analyze the potential negative impact on Monogram Orthopaedics Inc's future stock price. The final result cannot be summarized based on the provided input as there are no positive or negative keypoints to analyze. For more information, you can read the original text of Monogram Orthopaedics Inc's financial report: https://www.sec.gov/Archives/edgar/data/1769759/000110465923048956/xsl1-K_X01/primary_doc.xml

Bullish Points: 1. Monogram Orthopaedics is developing a product solution architecture to enable patient-optimized orthopaedic implants using 3D printing and robotics with advanced pre-operative imaging. 2. The company has a robot prototype that can autonomously execute optimized paths for high precision insertion of implants in synthetic bone specimens. 3. The total joint replacement devices market as of 2021 was approximately $19.4 billion globally, with the reconstructive joint replacement market expected to grow at an annual rate of between 3 and 3.4 percent. 4. Monogram aims to capitalize on the growing market for optimized press-fit implants combined with navigated robotic bone preparation. 5. The global market for Knee Joint Reconstruction Sales in 2021 was estimated to be $9.0 bill